Quick Takeaways
- JANUS HENDERSON GROUP PLC filed SCHEDULE 13G/A for ENTRADA THERAPEUTICS, INC. Common Stock (TRDA).
- Disclosed ownership: 5.6%.
- Date of event: 31 Mar 2025.
JANUS HENDERSON GROUP PLC - 31 Mar 2025 SCHEDULE 13G/A Report for ENTRADA THERAPEUTICS, INC. Common Stock (TRDA)
- Filing Manager
- JANUS HENDERSON GROUP PLC
- Reporting Manager
- JANUS HENDERSON GROUP PLC
- Symbol
- TRDA
- Shares outstanding
- 37,886,679 shares
- Disclosed Ownership
- 2,121,654 shares
- Ownership
- 5.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 May 2025, 12:28:53 UTC
- Date of event
- 31 Mar 2025
- Previous filing
- 14 Feb 2025
- Next filing
- 14 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"JANUS HENDERSON GROUP PLC disclosed 5.6% ownership in ENTRADA THERAPEUTICS, INC. Common Stock (TRDA) on 31 Mar 2025."
What Changed
- Previous schedule filing date: 14 Feb 2025.
- Current filing was accepted on 14 May 2025, 12:28.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 5.6% | 2,121,654 | 0 | 2,121,654 | Kristin Mariani | Head of North America Compliance, CCO | |
| Janus Henderson Biotech Innovation Master Fund Ltd | 5% | 1,884,826 | 0 | 1,884,826 | Kristin Mariani | Head of North America Compliance, CCO |